1. 106POncolysis dominated therapeutic effect of LCMV-GP – pseudotyped vesicular stomatitis virus in a syngeneic lung cancer model. (17th December 2018) Authors: Wollmann, G; Schreiber, L-M; Urbiola, C; Das, K; Spiesschaert, B; Kimpel, J; Heinemann, F; Stierstorfer, B; Müller, P; Petersson, M; Erlmann, P; von Laer, D Journal: Annals of oncology Issue: Volume 29(2018)Supplement 10 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 152P Replicative potency of oncolytic VSV-GP differentially shapes the immune signature in three distinct syngeneic tumour models. (15th December 2019) Authors: Wollmann, G; Spiesschaert, B; Das, K; Schreiber, L-M; Erlmann, P; Stierstorfer, B; von Laer, D; Mueller, P; Urbiola, C Journal: Annals of oncology Issue: Volume 30(2019)Supplement 11 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P09.15 Patient-derived head and neck tumor slice cultures – a versatile tool to study oncolytic virus action. (21st September 2022) Authors: Mayr, M; Runge, A; Schwaiger, T; Sprung, S; Chetta, P; Gottfried, T; Dudas, J; Greier, M; Glatz, M; Haybaeck, J; Elbers, K; Riechelmann, H; Erlmann, P; Petersson, M Journal: Journal for immunotherapy of cancer Issue: Volume 10(2022)Supplement 1 Page Start: A39 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗